| scholarly article | Q13442814 |
| P50 | author | Laurie Gutmann | Q38589707 |
| William J Meurer | Q43161011 | ||
| Thomas Tomsick | Q87999626 | ||
| Sidney Starkman | Q110243430 | ||
| P2093 | author name string | Jane Khoury | |
| Scott E Kasner | |||
| Steven R Levine | |||
| Steven Warach | |||
| Joseph P Broderick | |||
| Phillip A Scott | |||
| Alexander Schneider | |||
| Dawn Kleindorfer | |||
| Opeolu Adeoye | |||
| Brett C Meyer | |||
| James S McKinney | |||
| Thomas M Hemmen | |||
| Heidi Sucharew | |||
| Claudette E Brooks | |||
| Sharyl Martini | |||
| Arthur M Pancioli | |||
| Todd J Crocco | |||
| William A Knight | |||
| Pamela A Schmit | |||
| CLEAR-ER Investigators | |||
| P2860 | cites work | Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial | Q28185728 |
| Tissue plasminogen activator for acute ischemic stroke | Q29619377 | ||
| Optimizing the ongoing search for new treatments for Parkinson disease: using futility designs | Q30810700 | ||
| Making the right choice: optimizing rt-PA and eptifibatide lysis, an in vitro study. | Q34159021 | ||
| The combined approach to lysis utilizing eptifibatide and rt-PA in acute ischemic stroke: the CLEAR stroke trial | Q36986795 | ||
| Finding the most powerful measures of the effectiveness of tissue plasminogen activator in the NINDS tPA stroke trial | Q40744288 | ||
| Calibrated phase II clinical trials in oncology | Q41477121 | ||
| Effect of intravenous tirofiban and aspirin in reducing short-term and long-term neurologic deficit in patients with ischemic stroke: a double-blind randomized trial | Q43188064 | ||
| Safety of Tirofiban in acute Ischemic Stroke: the SaTIS trial | Q44237164 | ||
| Hemorrhagic transformation of ischemic brain tissue: asymptomatic or symptomatic? | Q48859420 | ||
| Emergency administration of abciximab for treatment of patients with acute ischemic stroke: results of an international phase III trial: Abciximab in Emergency Treatment of Stroke Trial (AbESTT-II) | Q79936656 | ||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | plasminogen | Q107129060 |
| P304 | page(s) | 2381-2387 | |
| P577 | publication date | 2013-07-25 | |
| P1433 | published in | Stroke Journal | Q7624282 |
| P1476 | title | Combined approach to lysis utilizing eptifibatide and recombinant tissue plasminogen activator in acute ischemic stroke-enhanced regimen stroke trial | |
| P478 | volume | 44 |
| Q33671141 | A matched comparison of eptifibatide plus rt-PA versus rt-PA alone in acute ischemic stroke |
| Q42857714 | Adjunctive medical therapies for acute stroke thrombolysis: is there a CLEAR-ER choice? |
| Q38127644 | Advances and challenges in treatment and prevention of ischemic stroke |
| Q34459133 | Advances in medical revascularisation treatments in acute ischemic stroke |
| Q38261206 | Alteplase in acute ischemic stroke: putting the guidelines into practice |
| Q40523644 | An Outcome Model for Intravenous rt-PA in Acute Ischemic Stroke |
| Q38790291 | Changing Management of Acute Ischaemic Stroke: the New Treatments and Emerging Role of Endovascular Therapy. |
| Q38243696 | Clinical trials in acute ischemic stroke |
| Q35998267 | Combined Approach to Lysis Utilizing Eptifibatide and Recombinant Tissue-Type Plasminogen Activator in Acute Ischemic Stroke-Full Dose Regimen Stroke Trial |
| Q50053948 | Combining Intravenous Thrombolysis and Antithrombotic Agents in Stroke: An Update. |
| Q38786616 | Effect of waivers of consent on recruitment in acute stroke trials: A systematic review |
| Q48458092 | Emergency and critical care management of acute ischaemic stroke |
| Q93081135 | From Discovery of Snake Venom Disintegrins to A Safer Therapeutic Antithrombotic Agent |
| Q51060040 | Glycoprotein IIb/IIIa Inhibitor Bridging and Subsequent Endovascular Therapy in Vertebrobasilar Occlusion in 120 Patients. |
| Q26797275 | Imaging of prehospital stroke therapeutics |
| Q38225341 | Intravenous thrombolysis in acute ischemic stroke: standard and potential future applications |
| Q41678659 | Low-dose intravenous tissue plasminogen activator for acute ischaemic stroke: an alternative or a new standard? |
| Q89563727 | Mobile Stroke Units: Bringing Treatment to the Patient |
| Q39106145 | Peptide hormones and lipopeptides: from self-assembly to therapeutic applications. |
| Q37670794 | Phase I and Phase II Therapies for Acute Ischemic Stroke: An Update on Currently Studied Drugs in Clinical Research |
| Q35019813 | Recombinant tissue-type plasminogen activator plus eptifibatide versus recombinant tissue-type plasminogen activator alone in acute ischemic stroke: propensity score-matched post hoc analysis |
| Q38170691 | Stroke: new horizons in treatment |
| Q33417854 | Targeting integrin and integrin signaling in treating thrombosis |
| Q38541197 | Treatment of acute stroke: an update |
| Q90538834 | Update in the Early Management and Reperfusion Strategies of Patients with Acute Ischemic Stroke |
| Q48558308 | Update on the effects of treatment with recombinant tissue-type plasminogen activator (rt-PA) in acute ischemic stroke. |
| Q26796472 | What is the Role for Intra-Arterial Therapy in Acute Stroke Intervention? |
Search more.